CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 60 enrolled
Drug / intervention
Neurl1 gene expression +1 moreother
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04865198
NCT04865198N/ACompleted

Role of Neuralized1 and RGS14 Genes With ASD Patients

TC Erciyes University·observational·Posted Apr 29, 2021·Updated Jul 26, 2022

In Brief

An observational study evaluating Neurl1 gene expression and RGS14 gene expression for Autism Spectrum Disorder and 2 related conditions. Completed, enrolled 60 participants.

Detailed Summary

Autism is a broad spectrum neurodevelopmental disease. Some individuals with ADS by high cognitive functions are diagnosed with High Functioning Autism (HFA). In some studies, it has been shown that NEURL1 gene increases learning and memory and RGS14 gene is suppressed them. We aimed to evaluate the differences between the expression levels of these genes between ASD, HFA and healthy controls and the role of these genes in the pathogenesis of ASD. Patients with 20 ASD and 20 HFA, and 20 healthy controls compatible with patient ages were included in this study. Expression of NEURL-1 and RGS14 genes was evaluated by quantitative Real Time PCR (qRT-PCR).

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
Countries--
Collaborators--

Timeline

N/ACompletedFinished
20132014201520162017201820192020202120222023202420252026
First PostedApr 29, 2021
Enrollment StartJan 10, 2013
Primary CompletionAug 30, 2014
TodayJul 2, 2026
Enrollment to primary: 1.6 yearsPosted 5.2 years ago

Interventions

Neurl1 gene expressionother

This observational case control study. The gene expression was examined.

RGS14 gene expressionother

This observational case control study. The gene expression was examined.